Study Of The Correlation Between TP53 Mutation And Induction Chemotherapy In Locally Advanced Oral Squamous Cell Carcinoma

Purpose: To investigate the status of TP53 mutations in locally advanced oral squamous cell carcinoma and explore its role as a predictive biomarker to screen patients who will benefit from induction chemotherapy.Methods: 101 patients with locally advanced OSCC treated in our hospital from 2008 to 2014 were included in this study.There were 74 men and 27 women with an age from 29 to 75 years(median,59 years).Their clinical information,frozen or FFPE samples of tumor biopsy and matched normal samples were collected in all patients.Using the Ion PGM system,all samples were sequenced with high-throughput technology for data of TP53 mutations which were then classified into different types.Torrent Suite Software v.5.0,Ion Reporter Software v.5.4 and SPSS v.23 were used to analyze the correlation between different TP53 mutations and clinical variables in OSCC patients.Results: The median follow-up time was 34.9 months with a range of 2.3-98 months.There were 102 TP53 non-synonymous mutations(allele frequency ? 3%)in 73 OSCC patients,with an average sequencing depth of 2366-fold in tumor samples and 2225-fold in matched normal samples.Compared with the 42 OSCC patients who did not receive induction chemotherapy,59 OSCC patients who received induction chemotherapy had a seemingly better distal metastasis free survival(DMFS,P=0.090)while no difference in overall survival.Subgroup analysis showed that patients with TP53 truncating mutations could benefit from induction chemotherapy in distal metastasis free survival(P=0.038).Multivariable logistic regression models did not show any significant predictors of response to induction chemotherapy in any of TP53 mutation types.Conclusions: Our study did not find that the patients with locally advanced OSCC could benefit from induction chemotherapy in overall survival,but TP53 truncating mutation could be a candidate for predictive biomarker to screen patients who will benefit from induction chemotherapy in distal metastasis free survival.